Each NeuroPI module is prepared by distinguished faculty who are acknowledge leaders in their respective fields. Each module is composed of a set of multiple-choice items with preferred responses, instructions on how to collect cases to assess one’s practice, and resources for creating and implementing an effective improvement plan. Participants are able to compare their performance pre- and post-intervention to assess what changes have occurred in their practice.
Members: FREE $199.00*
*Free access is limited to one course at a time for eligible members.
Category 1: Patients with a Diagnosis of multiple sclerosis
- Annual Assessment of Anxiety
- Annual Assessment for Bladder and Bowel Dysfunction
- Annual Assessment for Cognitive Dysfunction
- Annual Assessment of Depression
- Annual Assessment of Fatigue
- Annual Assessment of Mobility Dysfunction
- Annual Assessment of Sexual Dysfunction
- Annual Assessment of Spasticity
As a result of this program, the participant will determine individual practice gaps and address them through a performance improvement plan designed to improve competence, performance, and patient outcomes.
- Medical Knowledge
- Patient Care
- Practice-based Learning and Improvement
Date of Release
December 5, 2014
This module is eligible for CME credits for three years from the release date.
NeuroPI Data Terms & Conditions
The American Academy of Neurology Institute (AANI) no longer requires You (NeuroPI and aan.com user) to provide full date of service (day/month/year); only year of service will be transmitted to and stored by AANI. All previously collected "day" and "month" from date of service records have been deleted from the AANI's NeuroPI database. Accordingly, for NeuroPI, AANI is not requesting or storing any "protected health information" or "limited data sets" as defined by the regulations issued under the Health Insurance Portability and Accountability Act of 1996. The patient data You submit to the AANI through NeuroPI is de-identified health information. You must track patients separately from NeuroPI. Within the NeuroPI modules, Your patients will be identified using a 4-digit patient code that You create. Any other identifying information is strictly prohibited. Please use the NeuroPI Patient Tracker to create Your 4-digit patient codes for Your personal reference. The NeuroPI Patient Tracker must not be shared with AANI.
The American Academy of Neurology Institute either owns or has permission to use all of the NeuroPI module content. You may use these modules for your personal, noncommercial use, but please send permissions requests for any other uses to NeuroPI@aan.com. All of the individual de-identified health information you submit to the AANI through NeuroPI is confidential. Your maintenance of certification ("MOC") credit information is transmitted to the American Board of Psychiatry and Neurology (ABPN) once You've completed a module. You can opt-out of this service in NeuroTracker. Please note, AANI is not a certifying board and members are encouraged to contact ABPN for the most up-to-date information on MOC requirements. You acknowledge that AANI is and shall be deemed the owner of all rights to the aggregate, de-identified data submitted to NeuroPI and subsets of the aggregate data, any and all reports based on the aggregate, de-identified data, and all trademarks and trade secrets arising from or reflected in NeuroPI (collectively, "Aggregate Data"), with the exception of your individual data. AANI has full and unencumbered rights to publish, disclose, distribute, market, sell, and create derivatives of, Aggregate Data in any form.
CHRISTOPHER T. BEVER, JR, MD, MBA, CHAIR
Professor of Neurology, Pharmacology & Physical Therapy, University of Maryland School of Medicine and VA Maryland Health Care System, Baltimore, MD
*Dr. Bever has nothing to disclose.
BRUCE A. COHEN, MD, FAAN, FANA, FACP
Professor of Neurology, Davee Department of Neurology and Clinical Neurosciences, Northwestern University Feinberg School of Medicine, Chicago, IL
*Dr. Cohen has received personal compensation as a consultant with Accorda Therapeutics, EMD-Serono, Genetech, Questcor, and Teva Neuroscience.
+ Unlabeled use disclosure: Symptomatic agents used to treat fatigue or spasticity in multiple sclerosis which are approved for use in other conditions but not multiple sclerosis.
EDWARD J. GETTINGS, JR, DO
Fellow, Multiple Sclerosis Center of Excellence, Baltimore, MD
*Dr. Gettings has nothing to disclose.
DAVID MATTSON, MD, PhD, FAAN
Professor of Neurology & Director, Indiana University Multiple Sclerosis Center, Indiana University School of Medicine and IU Health, Indianapolis, IN
*Dr. Mattson has received speakers bureau compensation from Teva Neuroscience, Pfizer, Biogen-Idec, EMD-Serono, Accorda Therapeutics, Novartis, Bayer, and Genzyme. He has also received research support for clinical trials in multiple sclerosis from Teva Neuroscience, Biogen-Idec, Accorda Therapeutics, Novartis, Gentech, Roche, ONO, Sanofi-Aventis, Actelion, Medimmune, and Vaccinex.
DONALD J. IVERSON, MD, FAAN
Humboldt Neurological Medical Group, Eureka, California
*Dr. Iverson has received personal compensation for participation in the Accorda Therapeutics speaker's bureau.
RALPH F. JOZEFOWICZ, MD, FAAN
Chair, PIP Taskforce
University of Rochester, Rochester, New York
*Dr. Jozefowicz has received personal compensation in an editorial capacity for The Neurologist.
CYNTHIA L. COMELLA, MD, FAAN
Education Committee Chair
Rush University Medical Center, Chicago, Illinois
*Dr. Comella has received personal compensation for activities with Ipsen, Merz, Allergan, Inc., Medtronic, Inc., Teva Neuroscience, US World Meds, and Impax. Dr. Comella has received research support from Ipsen, Merz, Allergan, Inc., NIH, Dystonia Coalition, and Dystonia Medical Research Foundation.
JONATHAN P. HOSEY, MD, FAAN
Practice Committee Chair
Geisinger Medical Center, Danville, Pennsylvania
*Dr. Hosey has nothing to disclose.
Tracy King, MA, Associate Director, Education
*Ms. King has nothing to disclose.
Susan Rodmyre, Director, Education
*Ms. Rodmyre has nothing to disclose.
+ Unlabeled Use of Products/Investigational Use Disclosure